Prosecution Insights
Last updated: November 06, 2026
Application No. 17/714,082

Method and Apparatus for Regulating and Monitoring Discharge from a Syringe or Other Fluid Dispensing Apparatus

Final Rejection §103
Filed
Apr 05, 2022
Priority
Apr 06, 2021 — provisional 63/171,149
Examiner
NICHOLS, CHARLES W
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Safepush LLC
OA Round
2 (Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
206 granted / 370 resolved
-14.3% vs TC avg
Strong +55% interview lift
Without
With
+54.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
8 currently pending
Career history
409
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
63.6%
+23.6% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 370 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims This office action is in response to the amendment and remarks filed on 04/01/2026. In making the below rejections, the examiner has considered and addressed each of the applicants arguments. Claims 11-20 are withdrawn, and claims 1-10 have are being examined. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The drawing objection from the previous office action is withdrawn. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. PNG media_image1.png 764 554 media_image1.png Greyscale PNG media_image2.png 770 548 media_image2.png Greyscale Claims 1-10 are rejected under 35 U.S.C. 103 as being unpatentable over Haber (USPN 5,298,023) in view of Lynn (USPN 5,743,886). In reference to independent claim 1, Haber discloses an apparatus for regulating fluid flow rate from a fluid dispensing device (fig 31) comprising: a) a primary fluid chamber (654 and 520-496,510, fig 31b); b) an outlet (needle assembly 451) in fluid communication with said primary fluid chamber (654, fig 31b); c) a pump member (464, 514, 512, and 506) for displacing fluid from said primary fluid chamber (654) through said outlet (451); d) a secondary chamber (520-496 and 510) within said primary fluid chamber(654 and 520-496,510), said secondary chamber having no fluid within it (annotated fig 31a and 31b above clearly show locations with fluid in dashed lines, the secondary chamber as defined does not show any dashed lines meaning it has no fluid, furthermore when 512 is depressed the gap is exposed to ambient meaning there can’t be any fluid in the chamber); e) a dividing member (500) movably disposed in said secondary chamber (end of 510); f) a first adjustable volume (520 and 496) on a first side of said dividing member (below 500), wherein and g) a second adjustable volume (510) on a second side of said dividing member (500); wherein said dividing member (500) moves to increase said first adjustable volume (520 and 496) when fluid displaced through said outlet exceeds a predetermined flow rate (when the flow rate is too high it indicates the pressure to high which moves the plate up against the spring 504), however Haber does not teach said first volume is in fluid communication with said primary fluid chamber. Lynn, a similar syringe, teaches a first volume (66, fig 6C) is in fluid communication with said primary fluid chamber (primary fluid chamber 68, col 15 lines 21-29 disclose “When the injection of the fluid within the secondary reservoir 68 is complete, the divider piston 58 has reached the venting position and engages the seats 109. At this point, further advancement of the piston 38 causes the saline solution in the primary reservoir 66 to flow through the slots 104 and through the flush flow space 116 to flush around the lower face 59 of the divider piston 58 and out the distal conduit 18 and to flush the deadspace of the intravenous tubing and catheter with saline.”). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to use the slots 104 of Lynn in the apparatus of Haber “to specifically allow the aspiration of a capacitance storage volume of a flush volume, which can later be used to flush the deadspace of the reservoir and the deadspace of a tubing system and catheter” col 4, lines 28-31; Lynn. In reference to dependent claim 6, Haber discloses a fluid flow rate regulating syringe comprising: a) a barrel (494, fig 31) defining an inner chamber (654); b) an outlet (needle assembly 451) in fluid communication with said inner chamber of said barrel (when the needle assembly is extended it is fed by 654); c) a plunger (464, 514, 512, and 506) movably disposed in said barrel for displacing fluid through said outlet (col 16, lines 67-5 discloses “A needle assembly 451, assuming one is not already mounted to assembly 428, is then mounted to septum cap 446. The injection is then given by pressing on accumulator stem assembly 494 in distal direction 524, thereby forcing accumulator piston 464 in distal direction 524 to expulse the mixed pharmaceutical.”); d) a secondary chamber (520-496 and 510); e) a dividing member (500) movably disposed in said secondary chamber (520-496 and 510); f) a first adjustable volume (beneath 500) on a first side of said dividing member (500); and g) a second adjustable volume on a second side (above 500) of said dividing member (500); wherein said dividing member moves to increase said first adjustable volume when fluid displaced through said outlet exceeds a predetermined flow rate (when the flow rate is too high it indicates the pressure to high which moves the plate up against the spring 504). Haber does not teach said first volume is in fluid communication with said primary fluid chamber. Lynn, a similar syringe, teaches a first volume (66, fig 6C) is in fluid communication with said primary fluid chamber (primary fluid chamber 68, col 15 lines 21-29 disclose “When the injection of the fluid within the secondary reservoir 68 is complete, the divider piston 58 has reached the venting position and engages the seats 109. At this point, further advancement of the piston 38 causes the saline solution in the primary reservoir 66 to flow through the slots 104 and through the flush flow space 116 to flush around the lower face 59 of the divider piston 58 and out the distal conduit 18 and to flush the deadspace of the intravenous tubing and catheter with saline.”). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to use the slots 104 of Lynn in the apparatus of Haber “to specifically allow the aspiration of a capacitance storage volume of a flush volume, which can later be used to flush the deadspace of the reservoir and the deadspace of a tubing system and catheter” col 4, lines 28-31; Lynn. In reference to dependent claim 2, Haber in view of Lynn discloses the apparatus of claim 1, Haber discloses the apparatus further comprising a biasing member (504) for resisting movement of said dividing member (500). In reference to dependent claim 3, Haber in view of Lynn discloses the apparatus of claim 2, Haber discloses the apparatus wherein said biasing member comprises a constant force compression spring (504 is a spring, see fig 31a). In reference to dependent claim 4, Haber in view of Lynn discloses the apparatus of claim 1, Haber discloses the apparatus wherein said fluid dispensing device comprises a syringe (first line of abstract states “A multiple pharmaceutical syringe”). In reference to dependent claim 5, Haber in view of Lynn discloses the apparatus of claim 1, Haber discloses the apparatus further comprising a flow restriction (channel that connects 464 to 451) disposed between said primary fluid chamber (654 and 520-496,510) and said outlet (needle of 451). In reference to dependent claim 7, Haber in view of Lynn discloses the fluid regulating syringe of claim 6, Haber discloses the apparatus further comprising a biasing member (504) for resisting movement of said dividing member (500). In reference to dependent claim 8, Haber in view of Lynn discloses the fluid regulating syringe of claim 7, Haber discloses the apparatus wherein said biasing member (504) comprises a constant force compression spring (504 is a spring, see fig 31a). In reference to dependent claim 9, Haber in view of Lynn discloses the fluid regulating syringe of claim 6, Haber discloses the apparatus further comprising a flow restriction (channel that connects 464 to 451) disposed between said inner chamber of said barrel (654) and said outlet (needle of 451). In reference to dependent claim 10, Haber in view of Lynn discloses the fluid regulating syringe of claim 6, Haber discloses the apparatus wherein said secondary chamber (520-496 and 510) is disposed within said plunger (464, 514, 512, and 506). Response to Arguments In reference to applicant’s argument that “the device disclosed in Haber could not function as described in the office action. For example, the office action states that Haber discloses a dividing member (500) movably disposed in a secondary chamber (end of 510). However, as described in Haber, part number 500 is a plate secured to a proximal end of an accumulator stem. Haber col. 12, lines 49-51. The plate secured to a proximal end of the accumulator stem cannot be movably disposed within the chamber” examiner disagrees. Column 12, lines 1-10 clearly disclose “The use of plates 500, 506 and spring 504 permit the user to continue pressing on stem assembly 494 in a distal direction 524. Doing so permits plate 506 and guide sleeve 512 to move in distal direction 524 as suggested by the dashed lined position of assembly 494 in FIG. 29. This extra motion of accumulator stem assembly 494 causes spring 504 to compress; however, accumulator stem 498 is at the limit of its distal movement so that it, along with attached plate 500, remains in the position illustrated FIG. 31.” If chamber housing 512 is moving then the dividing member 500 can stay fixed and still be moving within the chamber. Furthermore, if the spring is compressed then the volume of the chamber has to change. In reference to applicant’s argument that “Conversely, the present invention is designed for delivering one fluid or pharmaceutical at a time at a controlled flow rate. The invention as claimed in claim 1 comprises a primary fluid chamber (15), an outlet (13), a pump member (20), a secondary chamber (22) having a dividing member (23) movably disposed within it. The dividing member (23) adjusts with changing pressure between the first and second adjustable volumes. The first adjustable volume, encompassing the space between dividing member 23 and outlet 13, contains the fluid to be delivered via the device, while the second adjustable volume, encompassing the space between thumb flange 27 and dividing member 23, adjusts as needed to prevent exceeding the predetermined flow rate as the fluid is displaced from the device.” Examiner agrees there are significant differences between applicant’s invention and Haber, however the test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981). That applicant’s device is a part of a larger device does not negate the fact that applicant’s claims are rendered obvious by it. In reference to applicant’s argument that “The second adjustable volume does not contain any fluid, it is meant to balance the changing fluid pressure as fluid is dispensed, thereby preventing an unintended excess in flow rate of the dispensed fluid. Claim 1 has been amended to clarify this limitation. Support for this amendment can be found, for example, at paragraphs [00065], [00068]-[00069].” Examiner cannot find any explicit declaration of this limitation in the spec or in the drawing. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES W NICHOLS whose telephone number is (571)272-6492. The examiner can normally be reached Monday-Friday 8am-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Tsai can be reached at (571) 270-5246. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.W.N/Examiner, Art Unit 3783 /WESLEY G HARRIS/Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Apr 05, 2022
Application Filed
Dec 01, 2025
Non-Final Rejection mailed — §103
Apr 01, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758240
IMPLANTATION CATHETER AND IMPLANTATION CATHETER ARRANGEMENT FOR HANDLING AN IMPLANT
4y 0m to grant Granted Oct 13, 2026
Patent 12751650
MEDICAL APPARATUS TO BE PLACED ON THE SURFACE OF A LIVING BODY AND AN INDWELLING DEVICE THAT INCLUDES SUCH A MEDICAL APPARATUS
3y 8m to grant Granted Oct 06, 2026
Patent 12741076
APPARATUS AND METHODS FOR PUNCTURING TISSUE AND REMOVING FLUIDS WITHOUT SPILLAGE
4y 7m to grant Granted Sep 22, 2026
Patent 12740545
ANIMAL FEEDING APPARATUS AND METHOD USING SAME
3y 8m to grant Granted Sep 22, 2026
Patent 12742412
SUPERCHARGER
3y 6m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
99%
With Interview (+54.9%)
4y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 370 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month